Posted by Michael Wonder on 01 May 2026
OS Therapies announces EMA initiates rolling review of conditional marketing authorisation application for OST-HER2 in the prevention or delay of recurrence in fully resected pulmonary metastatic osteosarcoma
30 April 2026 - OS Therapies today announced that the EMA's Committee for Advanced Therapy, in conjunction with the CHMP and Pharmacovigilance Risk Assessment Committee, has initiated Continuous Evaluation of the OST-HER2 conditional marketing authorisation request regulatory dossier for the prevention of recurrence in fully resected, pulmonary metastatic osteosarcoma.
The Company also announced that it was selected into EMA's Raw Data Pilot program.
